

Characteristics of International Cirrhosis Clinical Trials Reporting Data on Race and Ethnicity of Study Participants (n=118)

Author	Year	Intervention	Total Randomized	Sex (n, % total)		White	Black
				Male	Female		
Macken L <i>UK</i>	2020	Palliative long-term abdominal drains vs. LVP in refractory ascites due to cirrhosis	36	27 (75)	9 (25)	35 (97.2)	NR
Dunne PDJ <i>UK</i>	2020	Standard of care vs. early TIPSS in patients with cirrhosis and oesophageal variceal bleeding	58	39 (67.2)	19 (32.8)	NR	NR
Aamann L <i>Denmark</i>	2020	Resistance Training Increases Muscle Strength and Muscle Size in Patients With Liver Cirrhosis	39	30 (76.9)	9 (23.1)	NR	NR
Lv Y <i>China</i>	2019	Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis	129	87 (67.4)	42 (32.6)	NR	NR
Kumar M <i>India</i>	2020	Thromboelastography-Guided Blood Component Use in Patients With Cirrhosis With Nonvariceal Bleeding	96	78 (81.3)	18 (18.8)	NR	NR
Lv Y <i>China</i>	2018	Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis	49	29 (59.2)	20 (40.8)	NR	NR
Bureau C <i>Multicenter</i>	2017	Alfapump® system vs. large volume paracentesis for refractory ascites	58	46 (79.3)	12 (20.7)	NR	NR
Wang Q <i>China</i>	2017	Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding	127	78 (61.4)	49 (38.6)	NR	NR
Villanueva C <i>Spain</i>	2017	A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis	170	108 (63.5)	62 (36.5)	NR	NR
Bureau C <i>France</i>	2017	Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites	62	44 (71.0)	18 (29.0)	NR	NR

Escorsell A <i>Spain</i>	2016	Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial	28	25 (89.3)	3 (10.7)	NR	NR
Maharshi S <i>India</i>	2016	Efficacy of Nutritional Therapy for Patients With Cirrhosis and Minimal Hepatic Encephalopathy in a Randomized Trial	120	95 (79.2)	25 (20.8)	NR	NR
De Pietri L <i>Italy</i>	2016	Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy	60	38 (63.3)	22 (36.7)	NR	NR
Sauerbruch T <i>Germany</i>	2015	Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy	185	125 (67.6)	60 (32.4)	NR	NR
Zenith L <i>Canada</i>	2014	Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis	19	15 (78.9)	4 (21.1)	16 (84.2)	NR
Perarnau JM <i>France</i>	2014	Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt	136	102 (75.0)	34 (25.0)	NR	NR
Shah HA <i>Pakistan</i>	2014	Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage	168	122 (72.6)	46 (27.4)	NR	NR
Wigg AJ <i>Australia</i>	2013	Efficacy of a chronic disease management model for patients with chronic liver failure	60	40 (66.7)	20 (33.3)	NR	NR
Bañares R <i>Multicenter</i>	2013	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial	179	123 (68.7)	56 (31.3)	NR	NR
Dupont B <i>France</i>	2012	Randomised clinical trial: enteral nutrition does not improve the long-term outcome of alcoholic cirrhotic patients with jaundice	99	65 (65.7)	34 (34.3)	NR	NR
García-Pagán JC <i>Spain</i>	2010	Early use of TIPS in patients with cirrhosis and variceal bleeding	63	44 (69.8)	19 (30.2)	NR	NR
Riggio O <i>Italy</i>	2010	Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial	45	28 (62.2)	17 (37.8)	NR	NR
Licata G <i>Italy</i>	2009	Clinical Trial: High-dose furosemide + small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites	84	53 (63.1)	31 (36.9)	NR	NR

Lo GH <i>Taiwan</i>	2009	Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices	93	77 (82.8)	16 (17.2)	NR	NR
García-Pagán JC <i>Multicenter</i>	2009	Nadolol + isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding	158	118 (74.7)	40 (25.3)	NR	NR
Villanueva C <i>Spain</i>	2009	A randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy	59	38 (64.4)	21 (35.6)	NR	NR
Plank LD <i>Australia</i>	2008	Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis	103	85 (82.5)	18 (17.5)	NR	NR
Romero G <i>Argentina</i>	2006	Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients	109	72 (66.1)	37 (33.9)	NR	NR
Tan PC <i>Taiwan</i>	2006	A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation	97	69 (71.1)	28 (28.9)	NR	NR
Triantos C <i>Greece</i>	2005	Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers with endoscopic variceal ligation	52	38 (73.1)	14 (26.9)	NR	NR
Salerno F <i>Italy</i>	2004	Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites	66	49 (74.2)	17 (25.8)	NR	NR
Schepke M <i>Germany</i>	2004	Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis	152	104 (68.4)	48 (31.6)	NR	NR
Ginès P <i>Spain</i>	2002	Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis	70	50 (71.4)	20 (28.6)	NR	NR
Patch D <i>Multicenter</i>	2002	A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis	102	70 (68.6)	32 (31.4)	NR	NR
Lui HF <i>Scotland (UK)</i>	2002	Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate	172	97 (56.4)	75 (43.6)	NR	NR
Escorsell A <i>Spain</i>	2002	TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis	91	68 (74.7)	23 (25.3)	NR	NR

Pomier-Layrargues G <i>Canada</i>	2001	Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis	80	56 (70.0)	24 (30.0)	NR	NR
Escorsell A <i>Multicenter</i>	2000	Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study	219	158 (72.1)	61 (27.9)	NR	NR
Rössle M <i>Germany</i>	2000	A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites	60	42 (70.0)	18 (30.0)	NR	NR
Zuberi BF <i>Pakistan</i>	2000	Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low-risk cirrhosis	70	NR	NR	NR	NR
China L <i>UK</i>	2021	A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis	777	550 (70.8)	227 (29.2)	NR	NR
De A <i>India</i>	2021	Multiple Cycles of Granulocyte Colony-Stimulating Factor Increase Survival Times of Patients With Decompensated Cirrhosis in a Randomized Trial	100	85 (85.0)	15 (15.0)	NR	NR
Vijayaraghavan R <i>India</i>	2020	Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial	220	182 (82.7)	38 (17.3)	NR	NR
Arora V <i>India</i>	2020	Paracentesis-Induced Circulatory Dysfunction With Modest-Volume Paracentesis Is Partly Ameliorated by Albumin Infusion in Acute-on-Chronic Liver Failure	80	NR	NR	NR	NR
Fernández J <i>Multicenter</i>	2020	Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis	118	74 (62.7)	44 (37.3)	NR	NR
Villanueva C <i>Spain</i>	2019	$\beta$ blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial	201	123 (61.2)	78 (38.8)	NR	NR
Moreau R <i>France</i>	2018	Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis	291	202 (69.4)	89 (30.6)	NR	NR
Solà E <i>Spain</i>	2018	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial	173	137 (79.2)	36 (20.8)	NR	NR

Vidot H <i>Australia</i>	2018	Randomised clinical trial: oral taurine supplementation versus placebo reduces muscle cramps in patients with chronic liver disease	30	21 (70.0)	9 (30.0)	NR	NR
Arora V <i>India</i>	2020	Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure	120	113 (94.2)	7 (5.80)	NR	NR
Yim HJ <i>South Korea</i>	2018	Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial	124	90 (72.6)	34 (27.4)	NR	NR
Caraceni P <i>Italy</i>	2018	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial	431	296	135	NR	NR
El-Khayat H <i>Egypt</i>	2018	Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4	540	426 (78.9)	114 (21.1)	NR	NR
Verma N	2018	Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: A randomized trial	65	52 (80.0)	13 (20.0)	NR	NR
Sidhu SS	2018	L-ornithine L-aspartate in bouts of overt hepatic encephalopathy	193	173 (89.6)	20 (10.4)	NR	NR
Asselah T <i>Multicenter</i>	2016	Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial	184	130 (70.7)	54 (29.3)	NR	NR
Kim SG <i>South Korea</i>	2016	A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis	110	83 (75.5)	27 (24.5)	NR	NR
Sinclair M <i>Australia</i>	2016	Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial	101	101 (100)	0 (0.0)	92 (91.1)	NR
Bhardwaj A <i>India</i>	2017	Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial	140	119 (85.0)	21 (15.0)	NR	NR
Abraldes JG <i>Spain</i>	2016	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis	147	98 (66.7)	49 (33.3)	NR	NR

Merli M <i>Italy</i>	2016	An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial	94	67 (71.3)	27 (28.7)	NR	NR
Foster GR <i>Multicenter</i>	2015	Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection	592	395 (66.7)	197 (33.3)	495 (83.6)	6 (1.01)
Piano S <i>Italy</i>	2016	The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial	31	19 (61.3)	12 (38.7)	NR	NR
Kedarisetty CK <i>India</i>	2015	Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis	55	53 (96.4)	2 (3.63)	NR	NR
Cavallin M <i>Italy</i>	2015	Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial	48	32 (66.7)	16 (33.3)	NR	NR
Thévenot T <i>France</i>	2015	Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial	191	130 (68.1)	61 (31.9)	NR	NR
Poordad F <i>Multicenter</i>	2014	ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis	380	267 (70.3)	113 (29.7)	360 (94.7)	12 (3.20)
Seo YS <i>South Korea</i>	2014	Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage	780	666 (85.4)	114 (14.6)	NR	NR
Lunia MK <i>India</i>	2014	Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial	160	96 (0.60)	64 (0.40)	NR	NR
Sharma BC <i>India</i>	2013	A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy	120	89 (74.2)	31 (25.8)	NR	NR
Simón-Talero M <i>Spain</i>	2013	Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study	56	42 (75.0)	14 (25.0)	NR	NR
Singh V <i>India</i>	2013	Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study	60	56 (93.3)	4 (6.70)	NR	NR

Afdhal NH <i>Multicenter</i>	2012	Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia	292	188 (64.4)	104 (35.6)	178 (61.0)	NR
Villa E <i>Italy</i>	2012	Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis	70	51 (72.9)	19 (27.1)	NR	NR
Guevara M <i>Spain</i>	2012	Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study	97	62 (63.9)	35 (36.1)	NR	NR
Agrawal A <i>India</i>	2012	Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy	235	199 (84.7)	36 (15.3)	NR	NR
Singh V <i>India</i>	2012	Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study	40	37 (92.5)	3 (7.5)	NR	NR
Les I <i>Spain</i>	2011	Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study	116	88 (75.9)	28 (24.1)	NR	NR
Sidhu SS <i>India</i>	2011	Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial)	115	88 (76.5)	27 (23.5)	NR	NR
Khamaysi I <i>Israel</i>	2011	Sub-clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam: a randomized controlled study	91	50 (54.9)	41 (45.1)	NR	NR
Yang YY <i>Taiwan</i>	2010	Association of the G-protein and $\alpha$ 2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial	270	NR	NR	0	0
Lebrec D <i>France</i>	2010	Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis	342	NR	NR	NR	NR
Ginès P <i>Multicenter</i>	2010	Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study	148	103 (69.6)	45 (30.4)	NR	NR

Angeli P <i>Italy</i>	2010	Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial	100	67 (67.0)	33 (33.03)	NR	NR
Sharma BC <i>India</i>	2009	Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo	140	104 (74.3)	36 (25.7)	NR	NR
Abid S <i>Pakistan</i>	2009	Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial	324	NR	NR	NR	NR
Sanyal AJ <i>Multicenter</i>	2008	A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome	112	80 (71.4)	32 (28.6)	100 (89.3)	NR
Martín-Llahí M <i>Spain</i>	2008	Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study	46	29 (63.0)	17 (37.0)	NR	NR
Bosch J <i>Multicenter</i>	2008	Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial	256	187 (73.0)	69 (27.0)	NR	NR
Fernández J <i>Spain</i>	2007	Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis	68	45 (66.2)	23 (33.8)	NR	NR
Di Marco V <i>Italy</i>	2007	Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial	102	65 (63.7)	37 (36.3)	NR	NR
Prasad S <i>India</i>	2007	Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy	90	80 (88.9)	10 (11.1)	NR	NR
Spahr L <i>Switzerland</i>	2007	Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial	35	25 (71.4)	10 (28.6)	NR	NR
Fernández J <i>Spain</i>	2006	Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage	111	86 (77.5)	25 (22.5)	NR	NR
Lenaerts A <i>Belgium</i>	2006	Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system	61	40 (65.6)	21 (34.4)	NR	NR



Bolondi L <i>Italy</i>	2006	Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis	120	83 (69.2)	37 (30.8)	NR	NR
Angeli P <i>Italy</i>	2006	Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost	116	68 (58.6)	48 (41.4)	NR	NR
Muto Y <i>Japan</i>	2005	Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis	622	294 (47.3)	328 (52.7)	NR	NR
Fernández J <i>Spain</i>	2005	A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis	20	11 (55.0)	9 (45.0)	NR	NR
Riggio O <i>Italy</i>	2005	Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study	75	49 (65.3)	26 (34.7)	NR	NR
Gentile S <i>Italy</i>	2005	A randomized controlled trial of acarbose in hepatic encephalopathy	107	45 (42.1)	62 (57.9)	NR	NR
Bosch J <i>Spain</i>	2004	Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial	242	180 (74.4)	62 (25.6)	NR	NR
Merkel C <i>Italy</i>	2004	A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis	161	83 (51.6)	78 (48.4)	NR	NR
Liu Q <i>China</i>	2004	Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis	194	176 (90.7)	18 (9.3)	NR	NR
Santos J <i>Spain</i>	2003	Spirolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety	100	75 (75.0)	25 (25.0)	NR	NR
Marchesini G <i>Italy</i>	2003	Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial	174	110 (63.2)	64 (36.8)	NR	NR
García-Pagán JC <i>Spain</i>	2003	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT	349	241 (69.1)	108 (30.9)	NR	NR

Sola-Vera J <i>Spain</i>	2003	Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites	72	47 (65.3)	25 (34.7)	NR	NR
Pelletier G <i>France</i>	2003	A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice	226	139 (61.5)	87 (38.5)	NR	NR
Abecasis R <i>Argentina</i>	2003	Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study	100	55 (55.0)	45 (45.0)	NR	NR
Mas A <i>Spain</i>	2003	Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial	103	72 (69.9)	31 (30.1)	NR	NR
Bañares R <i>Spain</i>	2002	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis	51	34 (66.7)	17 (33.3)	NR	NR
Borroni G <i>Italy</i>	2002	Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites	52	37 (71.2)	15 (28.8)	NR	NR
Frossard JL <i>Switzerland</i>	2002	Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial	105	84 (80.0)	21 (20.0)	NR	NR
Calès P <i>France</i>	2001	Early administration of vapreotide for variceal bleeding in patients with cirrhosis	196	148 (75.5)	48 (24.5)	NR	NR
Ricart E <i>Spain</i>	2000	Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients	80	37 (46.3)	43 (53.8)	NR	NR
Li CP <i>China</i>	2000	Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study	16	16 (100)	0 (0.0)	NR	NR
Junquera F <i>Spain</i>	2000	Somatostatin plus isosorbide 5-mononitrate versus somatostatin in the control of acute gastro-oesophageal variceal bleeding: a double blind, randomised, placebo controlled clinical trial	60	43 (71.7)	17 (28.3)	NR	NR









NR	NR	NR	NR	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	9 (4.90)
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR

NR	NR	NR	NR	NR
80 (13.5)	2 (0.33)	3 (0.5)	2 (0.33)	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR
8 (2.1)	NR	NR	NR	45 (11.8)
780 (100)	NR	NR	NR	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR
NR	NR	NR	NR	NR









